Immunotherapy | Tumor

CURE’s immunotherapy page features the latest cancer news and updates on immunotherapy Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in immunotherapy.

FDA Agrees to Review Opdivo for Post-Surgical Melanoma Treatment

March 8th 2023, 10:00pm

Article

The Food and Drug Administration accepted a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.

Immunotherapy Effectiveness Tied to Particular Cell Activity

March 7th 2023, 10:00pm

Article

Patients who do not respond to immunotherapy have reduced CD5 activity in their tumors, opening the door for more effective immunotherapy treatments.

Keytruda Misses Outcomes in Two Clinical Trials

March 1st 2023, 2:00pm

Article

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

A Better Treatment May Exist for Immunotherapy-Related Heart Problems

February 23rd 2023, 2:00pm

Article

Standard corticosteroid use may not be the best treatment for patients with cancer who experience immunotherapy-related heart issues, research showed.

Keytruda Approval Offers ‘Another Form of Insurance’ to Keep Lung Cancer From Returning

February 8th 2023, 2:11pm

Article

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

Biomarker Algorithm May Predict Immunotherapy Outcomes Across Cancer Types

February 7th 2023, 10:00pm

Article

A new tool may identify more patients with cancer who can benefit from immunotherapy.

Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modest

February 2nd 2023, 8:00pm

Article

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

Low-Dose Immunotherapy Boosts Survival in Head and Neck Cancer

January 25th 2023, 10:00pm

Article

Opdivo — even when given in a low dose — was shown to improve outcomes in patients with advanced head and neck squamous cell carcinoma, highlighting a new option for patients who cannot receive the full dose.

Researchers Are ‘Building Up the Wall of Evidence’ to Support Cancer Vaccines in the Future

January 25th 2023, 8:00pm

Article

As more news is released about studies assessing cancer vaccines, one expert explains what this may mean for patients in the future.

Opdivo Improves Time to Disease Recurrence in Stage 2B and 2C Skin Cancer

October 20th 2022, 7:00pm

Article

When given after surgery, Opdivo improved relapse-free survival compared to placebo in patients with stage 2B or 2C skin cancer, according to recent results from the CheckMate-76K clinical trial.